Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.
PLoS One
; 18(11): e0290876, 2023.
Article
in En
| MEDLINE
| ID: mdl-37963146
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Depressive Disorder, Major
/
Depressive Disorder, Treatment-Resistant
/
Ketamine
Limits:
Adolescent
/
Adult
/
Humans
Country/Region as subject:
Oceania
Language:
En
Journal:
PLoS One
Journal subject:
CIENCIA
/
MEDICINA
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: